An Electrochemical Sensor Based on AuNPs@Cu-MOF/MWCNTs Integrated Microfluidic Device for Selective Monitoring of Hydroxychloroquine in Human Serum

Abstract

Hydroxychloroquine (HCQ), a cornerstone therapeutic agent for autoimmune diseases, requires precise serum concentration monitoring due to its narrow therapeutic window. Current HCQ monitoring methods such as HPLC and LC-MS/MS are sensitive but costly and complex. While electrochemical sensors offer rapid, cost-effective detection, their large chambers and high sample consumption hinder point-of-care use. To address these challenges, we developed a microfluidic electrochemical sensing platform based on a screen-printed carbon electrode (SPCE) modified with a hierarchical nanocomposite of gold nanoparticles (AuNPs), copper-based metal–organic frameworks (Cu-MOFs), and multi-walled carbon nanotubes (MWCNTs). The Cu-MOF provided high porosity and analyte enrichment, MWCNTs established a 3D conductive network to enhance electron transfer, and AuNPs further optimized catalytic activity through localized plasmonic effects. Structural characterization (SEM, XRD, FT-IR) confirmed the successful integration of these components via π-π stacking and metal–carboxylate coordination. Electrochemical analyses (CV, EIS, DPV) revealed exceptional performance, with a wide linear range (0.05–50 μM), a low detection limit (19 nM, S/N = 3), and a rapid response time (<5 min). The sensor exhibited outstanding selectivity against common interferents, high reproducibility (RSD = 3.15%), and long-term stability (98% signal retention after 15 days). By integrating the nanocomposite-modified SPCE into a microfluidic chip, we achieved accurate HCQ detection in 50 μL of serum, with recovery rates of 95.0–103.0%, meeting FDA validation criteria. This portable platform combines the synergistic advantages of nanomaterials with microfluidic miniaturization, offering a robust and practical tool for real-time therapeutic drug monitoring in clinical settings.